About: Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)
Creator	Abbas, Hassan Aljabory, Adnan Almashhadani, Marwan Dakhil, Basim Ghanim, Mohammed »more»
source	MedRxiv
abstract	Background: To date no effective therapy has been demonstrated for COVID-19. In vitro, studies indicated that ivermectin (IVM) has antiviral effect. Objectives: To assess the effectiveness of ivermectin (IVM) as add-on therapy to hydroxychloroquine (HCQ) and azithromycin (AZT) in treatment of COVID-19. Methods: This Pilot clinical trial conducted on hospitalized adult patients with mild to moderate COVID-19 diagnosed according to WHO interim guidance. Sixteen Patients received a single dose of IVM 200Mcg /kg on admission day as add on therapy to hydroxychloroquine ( HCQ)and Azithromycin (AZT) and were compared with 71 controls received HCQ and AZT matched in age, gender, clinical features, and comorbidities. The primary outcome was percentage of cured patients, defined as symptoms free to be discharged from the hospital and 2 consecutive negative PCR test from nasopharyngeal swabs at least 24 hours apart. The secondary outcomes were time to cure in both groups and evaluated by measuring time from admission of the patient to the hospital till discharge. Results: Of 87 patients included in the study,t he mean age {+/-} SD (range) of patients in the IVM group was similar to controls [44.87 {+/-} 10.64 (28-60) vs 45.23 {+/-} 18.47 (8-80) years, p=0.78] Majority of patients in both groups were male but statistically not significant [11(69%) versus 52 (73%), with male: female ratio 2.21 versus 2.7-, p=0.72) All the patients of IVM group were cured compared with the controls [ 16 (100 %) vs 69 (97.2 %)]. Two patients died in the controls. The mean time to stay in the hospital was significantly lower in IVM group compared with the controls (7.62 {+/-}2.75 versus 13.22 {+/-}.90 days, p=0.00005, effect size= 0.82). No adverse events were observed Conclusions : Add-on use of IVM to HCQ and AZT had better effectiveness, shorter hospital stay, and relatively safe compared with controls. however, a larger prospective study with longer follow up may be needed to validate these results.
has issue date	2020-07-08(xsd:dateTime)
bibo:doi	10.1101/2020.07.07.20145979
has license	medrxiv
sha1sum (hex)	c9f116b5d707949517db3c6efcfe5f2081a86b87
schema:url	https://doi.org/10.1101/2020.07.07.20145979
resource representing a document's title	Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)
resource representing a document's body	covid:c9f116b5d707949517db3c6efcfe5f2081a86b87#body_text
is schema:about of	named entity 'Azithromycin' named entity 'therapy' named entity 'patients' named entity 'effectiveness' named entity 'study' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software